MAZE Stock — Maze Therapeutics, Inc.

Maze Therapeutics, Inc. (MAZE)

Updated October 16, 2026.

MAZE is a Stock. Total return is 72.1% over the past 1.7 years, 43.5 points ahead of SPY at 28.6%.

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases, with lead programs in phase II trials targeting conditions including APOL1 kidney disease, phenylketonuria, chronic kidney disease, and Pompe disease. As an early-stage biotech company, it does not currently distribute to shareholders. This security appeals to investors with high risk tolerance seeking exposure to early-stage drug development rather than current income.

MAZE performance versus SPY

Price and return data through 2026-10-16.

Total return is 72.1% over the past 1.7 years, 43.5 points ahead of SPY at 28.6%. Over the past year its total return — price change plus distributions reinvested — is -3.2%. Its deepest 1-year drawdown was 56.8%.

MAZE key facts

Asset type

Stock

Asset class

Equity

Inception date

01/30/2025

Distribution frequency

None

Last close

$27.53 (as of 2026-10-16)

Market cap

$1,529,268,595

Average volume

1018481.0

Payout ratio

0.0%

Forward P/E

8.5324

EPS

$-2.48

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MAZE risks and drawbacks

The deepest 1-year drawdown on record here is 56.8%.

Who may consider MAZE — and who may not

It is a weaker fit for investors who need monthly cash flow (MAZE does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on MAZE

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions